151 related articles for article (PubMed ID: 29389083)
1. Are we any closer to treating liver fibrosis (and if no, why not)?
Feng R; Yuan X; Shao C; Ding H; Liebe R; Weng HL
J Dig Dis; 2018 Mar; 19(3):118-126. PubMed ID: 29389083
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma.
Li H
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):217-233. PubMed ID: 33131349
[No Abstract] [Full Text] [Related]
3. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
4. Liver fibrosis: a dynamic and potentially reversible process.
Povero D; Busletta C; Novo E; di Bonzo LV; Cannito S; Paternostro C; Parola M
Histol Histopathol; 2010 Aug; 25(8):1075-91. PubMed ID: 20552556
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients.
Ratti L; Pozzi M; Bosch J
Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033
[TBL] [Abstract][Full Text] [Related]
6. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic evaluation of liver biopsy for cirrhosis.
Ma C; Brunt EM
Adv Anat Pathol; 2012 Jul; 19(4):220-30. PubMed ID: 22692285
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
Thabut D; Shah V
J Hepatol; 2010 Nov; 53(5):976-80. PubMed ID: 20800926
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological approach to reverse portal hypertention and hepatic schistosomal fibrosis in Egypt, control experimental study.
Helmy AH; Abdel-Hady AA; el-Shanawany F; Hammam O; Abdel-Hady A
J Egypt Soc Parasitol; 2005 Dec; 35(3):731-50. PubMed ID: 16333884
[TBL] [Abstract][Full Text] [Related]
10. Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters.
Bolognesi M; Sacerdoti D; Mescoli C; Bombonato G; Cillo U; Merenda R; Giacomelli L; Merkel C; Rugge M; Gatta A
Scand J Gastroenterol; 2007 Feb; 42(2):256-62. PubMed ID: 17327946
[TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis-related cirrhosis.
Leung DH; Narkewicz MR
J Cyst Fibros; 2017 Nov; 16 Suppl 2():S50-S61. PubMed ID: 28986027
[TBL] [Abstract][Full Text] [Related]
12. [The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis].
Lee JS; Kim JH
Korean J Hepatol; 2007 Sep; 13(3):309-19. PubMed ID: 17898548
[TBL] [Abstract][Full Text] [Related]
13. New cellular and molecular targets for the treatment of portal hypertension.
Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
[TBL] [Abstract][Full Text] [Related]
14. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles.
Lemoinne S; Cadoret A; Rautou PE; El Mourabit H; Ratziu V; Corpechot C; Rey C; Bosselut N; Barbu V; Wendum D; Feldmann G; Boulanger C; Henegar C; Housset C; Thabut D
Hepatology; 2015 Mar; 61(3):1041-55. PubMed ID: 25043701
[TBL] [Abstract][Full Text] [Related]
15. Impact of etiological treatment on prognosis.
Su CW; Yang YY; Lin HC
Hepatol Int; 2018 Feb; 12(Suppl 1):56-67. PubMed ID: 28702738
[TBL] [Abstract][Full Text] [Related]
16. Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cells.
Brückner S; Zipprich A; Hempel M; Thonig A; Schwill F; Roderfeld M; Roeb E; Christ B
Cytotherapy; 2017 Dec; 19(12):1462-1473. PubMed ID: 29074333
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
18. Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension.
Klein S; Schierwagen R; Uschner FE; Trebicka J
Methods Mol Biol; 2017; 1627():91-116. PubMed ID: 28836197
[TBL] [Abstract][Full Text] [Related]
19. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis.
Moreno-Merlo F; Wanless IR; Shimamatsu K; Sherman M; Greig P; Chiasson D
Hepatology; 1997 Sep; 26(3):554-60. PubMed ID: 9303482
[TBL] [Abstract][Full Text] [Related]
20. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
